Filing Impact
Filing Sentiment
Form Type
4
Jasper Therapeutics Inc
Aug 13, 2025
Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Jul 9, 2025
Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway
Jul 11, 2025
[SCHEDULE 13G] Jasper Therapeutics, Inc. SEC Filing
42.81M
14.83M
1.27%
89.66%
9.02%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
REDWOOD CITY